Pandemic Anti-Monopoly Act of 2020
Latest action · May 22, 2020 Referred to the House Committee on the Judiciary.
Progress
Where this bill reached, and when. A stage with no date was not reached; one that failed a vote and later carried shows the date it carried.
- IntroducedMay 22, 2020
- Passed HouseNot reached
- Passed SenateNot reached
- To the PresidentNot reached
- Became lawNot reached
Summary
Pandemic Anti-Monopoly Act of 2020
This bill places a moratorium on certain mergers and acquisitions during the COVID-19 (i.e., coronavirus disease 2019) pandemic.
Specifically, the bill prohibits certain transactions such as acquisitions (1) by firms with over $100 million in revenue; (2) by financial institutions or equity funds with over $100 million in capitalization; and (3) involving firms with exclusive patents pertaining to COVID-19 pandemic-related production, manufacturing, distribution, or infrastructure. However, a waiver may be granted if the participating firms demonstrate that the transaction will advance critical national security, economic, or public health interests during the emergency.
Further, the bill establishes a legal presumption against a transaction that may pose a risk to the government's ability to respond to the national emergency declared due to COVID-19.
Cosponsors 2
Members who signed on, in the order they did. All signed on May 22, 2020.
| Seat | Cosponsor | Signed on | |
|---|---|---|---|
| D-MN | Ilhan Omar | Original | May 22, 2020 |
| D-IL | Jesús G. "Chuy" García | Original | May 22, 2020 |
Committees 1
Where it was sent and what each committee and subcommittee did with it, in order.
| Chamber | Committee | What it did |
|---|---|---|
| House | Judiciary Committee | Referred May 22, 2020 |
Actions 2
Everything that happened, newest first.
- May 22, 2020Introduced in House
- May 22, 2020Referred to the House Committee on the Judiciary.
Research
What has been written about this bill: committee reports, cost estimates, the sponsor’s authority statement, printed hearings and the Congressional Research Service’s work.
Constitutional authority
The sponsor’s statement, as printed in the Congressional Record, vol. 166, no. 97, May 22, 2020, page H2278.
Titles 2
Every title it has carried, official and short, at each stage.
- Official Title as Introduced
- To prohibit certain transactions during the coronavirus disease 2019 (COVID-19) pandemic.
- Short Title(s) as Introduced
- Pandemic Anti-Monopoly Act of 2020
Subjects
Assigned by the Library of Congress. Policy area: Commerce.
- Administrative law and regulatory procedures
- Administrative remedies
- Banking and financial institutions regulation
- Cardiovascular and respiratory health
- Civil actions and liability
- Commerce
- Competition and antitrust
- Corporate finance and management
- Drug safety, medical device, and laboratory regulation
- Emergency medical services and trauma care
- Federal Trade Commission (FTC)
- Financial services and investments
- Health technology, devices, supplies
- Infectious and parasitic diseases
- Intellectual property
- Manufacturing
- Product development and innovation
- Public contracts and procurement
- Research and development
- Strategic materials and reserves
Text 1
Each version as it was printed, newest first.
- May 22, 2020Introduced in House
Everything here is as published by Congress: the summary is the Congressional Research Service's, the action wording is the clerks', and the subjects are the Library of Congress's. How far it got is read from the actions themselves, taking the most recent one of each kind, so a bill that failed a vote and later passed is shown as having passed. Records come from this bill on Congress.gov and govinfo.gov; cost estimates are the Congressional Budget Office's, and the hearings are the printed hearings GovInfo publishes, which can appear months after the hearing.